Tegaserod and IBS: a perfect match?

Thompson, W. Grant
May 2003
Gut;May2003, Vol. 52 Issue 5, p621
Academic Journal
Reports on the clinical trials concerning how well the drug tegaserod, matches the needs of irritable bowel syndrome patients. Comparison of the primary outcome measures derived from the trials; Features of the drug.


Related Articles

  • Salix Begins Phase III Studies with Rifaximin. Turner, Tiffany // BioWorld Today;7/2/2008, Vol. 19 Issue 128, p1 

    The article announces that Salix Pharmaceuticals Ltd. has begun initiating enrollment in two Phase III studies for the assessment of the efficacy and safety of rifaximin, in July 2008. Rifaximin is a treatment for nonconstipation irritable bowel syndrome (IBS). Executive director of investor...

  • Furiex Pharmaceuticals Study Results to be Presented at the American College of Gastroenterology 2011 Annual Scientific Meeting.  // Biomedical Market Newsletter;10/31/2011, Vol. 21, p61 

    The article reports on the presentation of the results of the phase II proof-of-concept clinical trial conducted by Furiex Pharmaceuticals Inc. It notes that the results of the clinical trial, which evaluates the safety and efficacy of MuDelta, will be presented at the American College of...

  • FDA Advisory Committee Supports Proposed Clinical Trial Design to Evaluate Repeat Treatment Cycles of XIFAXAN(r) for Irritable Bowel Syndrome with Diarrhea.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p455 

    The article reports on the support of the U.S. Food and Drug Administration's (FDA) Gastrointestinal Drug Advisory Committee to the proposed clinical trial by Salix Pharmaceuticals Ltd. for drug rifaxan or rifaximin. The clinical trial will evaluate repeat treatment cycles of such drug for...

  • Another agent for IBS in late-stage development.  // Formulary;Aug99, Vol. 34 Issue 8, p642 

    Reports on the result of the phase III trial for the drug HTF 919 used for the treatment of irritable bowel syndrome.

  • More therapies for IBS symptoms coming. Belden, Heidi // Drug Topics;2/5/2007, Vol. 151 Issue 3, p25 

    The article focuses on various drugs developed for the treatment of irritable bowel syndrome (IBS) in the U.S. Pharmaceutical firm Alizyme Therapeutics PLC is on the process of testing its drug called renzapride designed to increase the frequency of bowel movements for patients with constipation...

  • Review: Tegaserod or alosetron is effective for the irritable bowel syndrome. Rubenstein, Joel H.; Chey, William D. // ACP Journal Club;Mar/Apr2003, Vol. 138 Issue 2, p50 

    Presents therapies and diagnostic strategies for patients with irritable bowel syndrome (IBS). Details of the randomized controlled trials used in the study; Possible medications for IBS; Application of alosetron and tegaserod on IBS patients.

  • Tegaserod meta-analysis: Global relief of IBS symptoms, no increase in abdominal surgery.  // Formulary;Jul2002, Vol. 37 Issue 7, p341 

    Discusses results of the clinical phase three trials involving the serotonin receptor agonist tegaserod, for the relief of the symptoms of constipation-predominant irritable bowel syndrome. Percentage of patients included in the study who experienced symptom relief; Absence of a link between...

  • Probiotics and irritable bowel syndrome. Korpela, Riitta; Niittynen, Leena // Microbial Ecology in Health & Disease;2012, Vol. 23, p19 

    Background: Irritable bowel syndrome (IBS) is a major cause of abdominal discomfort and gut dysfunction worldwide. It is a poorly understood functional gastrointestinal disorder for which no effective medication is available. It is a benign condition, but its social and economic burden is...

  • Tioga Nabs $18M from VCs for Phase III Irritable Bowel Studies. Morrison, Trista // BioWorld Today;2/18/2010, Vol. 21 Issue 32, p1 

    The article reports on the 18 million U.S. dollars raised by Tioga Pharmaceuticals Inc. in a second round of venture financing which will be used to complete a Phase III trial with asimadoline for diarrhea predominant irritable bowel syndrome (D-IBS). The San Diego, California-based...


Read the Article


Sign out of this library

Other Topics